ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

NCT04645069 PHASE1, PHASE2 COMPLETED

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

Details

Lead sponsor	Adagene Inc
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	58
Start date	Mon Mar 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced/Metastatic Solid Tumors

Interventions

• ADG126 Mono
• ADG126-anti PD1
• ADG126-ADG106

Countries

Singapore, United States, Australia